The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...

Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...